Association of Serum Copper Levels and Amine Oxidase Copper Gene 1 (AOC1) with Migraineurs

Anne Sahithi Somavarapu Thomas, Radha Saraswathy, Anuhya Anne, Muthu Thayanithy

Abstract

Migraine is a common neurovascular multifactorial disease with biochemical abnormalities in the central nervous system (CNS). It is characterized by episodes of frequent headaches, affecting about 14% of the world's population. Trace elements are essential to play an important role in neurotransmission and causing oxidative stress in patients with migraine. Also, it is hypothesized that Histamine (biogenic amine), catabolized by Diamine oxidase (DAO), induces a vascular headache. DAO contains Copper as a cofactor and is coded by the Amine oxidase copper containing 1 (AOC1) gene. This study aims to determine the level of serum copper (Cu), an association of the AOC1 gene and antioxidant capacity in migraine patients. In this study, a total number of 200 individuals (patients and controls) were equally distributed in each group according to demographic details obtained. The results obtained from this study were found to be significant to migraine. The frequency of T allele (rs10156191) in exon 4 AOC1 was 7.5% in migraineurs OR of 16.13; 95% CI- 0.63 to 47.97, and the p-value was observed to be 0.074. The mean concentration of Cu was found to be 0.09 ± 0.02 mg/L and 0.22 ± 0.10 mg/L in patients and controls, respectively. Antioxidant capacity of serum was found to be lower in patients (3 ± 1.2 μM ascorbic acid equivalents) when compared to controls (7 ± 0.9 μM ascorbic acid equivalents). Decreased Cu and a nonsynonymous of rs10156191 are associated with migraine, which may decrease in DAO activity. Further research, needs to be focused on the DAO activity that can determine the migraine-inducing effect.

Keywords

References

[1] P. J. Goadsby, P. R. Holland, M. Martins-Oliveira, J. Hoffmann, C. Schankin, and S. Akerman, “Pathophysiology of migraine: A disorder of sensory processing,” Physiological Reviews, vol. 97, no. 2, pp. 553–622, Apr. 2017.

[2] R. Gupta and M. Bhatia, “Comparison of clinical characteristics of migraine and tension type headache,” Indian Journal of Psychiatry. vol. 53, no. 2, p. 134, 2011.

[3] T. J. Steiner, L. J. Stovner, R. Jensen, D. Uluduz, and Z. Katsarava, “Migraine remains second among the world’s causes of disability, and first among young women: Findings from GBD2019,” The Journal of Headache and Pain, vol. 21, no. 1, p. 137, 2020.

[4] R. Potter, K. Probyn, C. Bernstein, T. Pincus, M. Underwood, and M. Matharu, “Diagnostic and classification tools for chronic headache disorders: A systematic review,” Cephalalgia, vol. 39, no. 6, pp. 761–784, 2019.

[5] S. T. A. Sahithi, T. Muthu, and R. Saraswathy, “Migraine: Update and future perspectives,” International Journal of Nutrition, Pharmacology, Neurological Diseases, vol. 10, no. 4, pp. 179–187, 2020.

[6] P. Goadsby, “Pathophysiology of migraine,” Annals of Indian Academy of Neurology, vol. 15, no. 5, p. 15, 2012.

[7] P. J. Goadsby, P. R. Holland, M. Martins-Oliveira, J. Hoffmann, C. Schankin, and S. Akerman, “Pathophysiology of migraine: A disorder of sensory processing,” Physiological Reviews, vol. 97, no. 2, pp. 553–622, 2017.

[8] P. Martelletti, R. Burstein, and F. Pierelli, “12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches,” The Journal of Headache and Pain, vol. 19, no. S1, p. 80, 2018, doi: 10.1186/s10194-018-0900-0.

[9] C. Gasparini, H. Sutherland, and L. Griffiths, “Studies on the pathophysiology and genetic basis of migraine,” Current Genomics, vol. 14, no. 5, pp. 300–315, 2013.

[10] H. Himmerich, J. Bentley, C. Kan, and J. Treasure, “Genetic risk factors for eating disorders: An update and insights into pathophysiology,” Therapeutic Advances in Psychopharmacology, vol. 9, p. 204512531881473, 2019.

[11] S. E. Erdener and T. Dalkara, “Modelling headache and migraine and its pharmacological manipulation,” British Journal of Pharmacology, vol. 171, no. 20, pp. 4575–4594, 2014.

[12] X. Lv, Z. Wu, and Y. Li, “Innervation of the cerebral dura mater,” The Neuroradiology Journal, vol. 27, no. 3, pp. 293–298, 2014.

[13] F. A. Pinho-Ribeiro, W. A. Verri, and I. M. Chiu, “Nociceptor sensory neuron–immune interactions in pain and inflammation,” Trends in Immunology, vol. 38, no. 1, pp. 5–19, 2017.

[14] R. Malhotra, “Understanding migraine: Potential role of neurogenic inflammation,” Annals of Indian Academy of Neurology, vol. 19, no. 2, p. 175, 2016.

[15] H. Kleij and J. Bienenstock, “Significance of conversation between mast cells and nerves,” Allergy, Asthma & Clinical Immunology, vol. 1, no. 2, p. 65, 2005.

[16] A. C. C. C. Branco, F. S. Y. Yoshikawa, A. J. Pietrobon, and M. N. Sato, “Role of histamine in modulating the immune response and inflammation,” Mediators of Inflammation, vol. 2018, pp. 1–10, 2018.

[17] A. Pino-Ángeles, A. Reyes-Palomares, E. Melgarejo, and F. Sánchez-Jiménez, “Histamine: An undercover agent in multiple rare diseases?,” Journal of Cellular and Molecular Medicine, vol. 16, no. 9, pp. 1947–1960, 2012.

[18] A. P. McGrath, K. M. Hilmer, C. A. Collyer, E. M. Shepard, B. O. Elmore, D. E. Brown, D. M. Dooley, and J. M. Guss, “Structure and inhibition of human diamine oxidase,” Biochemistry, vol. 48, no. 41, pp. 9810–9822, 2009.

[19] L. Maintz and N. Novak, “Histamine and histamine intolerance,” The American Journal of Clinical Nutrition, vol. 85, no. 5, pp. 1185–1196, 2007.

[20] O. Comas-Basté, S. Sánchez-Pérez, M. T. Veciana-Nogués, M. Latorre-Moratalla, and M. del C. Vidal-Carou, “Histamine intolerance: The current state of the art,” Biomolecules, vol. 10, no. 8, p. 1181, 2020.

[21] R. H. Kretsinger, V. N. Uversky, and E. A. Permyakov, Encyclopedia of Metalloproteins. New York: Springer, 2013.

[22] B. O. Elmore, J. A. Bollinger, and D. M. Dooley, “Human kidney diamine oxidase: Heterologous expression, purification, and characterization,” JBIC Journal of Biological Inorganic Chemistry, vol. 7, no. 6, pp. 565–579, 2002.

[23] L. Maintz, C.-F. Yu, E. Rodríguez, H. Baurecht, T. Bieber, T. Illig, S. Weidinger, and N. Novak, “Association of single nucleotide polymorphisms in the diamine oxidase gene with diamine oxidase serum activities,” Allergy, vol. 66, no. 7, pp. 893– 902, 2011.

[24] J. A. G. Agúndez, P. Ayuso, J. A. Cornejo-García, M. Blanca, M. J. Torres, I. Doña, M. Salas, N. Blanca-López, G. Canto, C. Rondon, P. Campo, J. J. Laguna, J. Fernández, C. Martínez, and E. García-Martín, “The diamine oxidase gene is associated with hypersensitivity response to nonsteroidal anti-inflammatory drugs,” PLoS ONE, vol. 7, no. 11, p. e47571, 2012.

[25] A. Charles and K. C. Brennan, “The neurobiology of migraine,” Handbook of Clinical Neurology, vol. 97, pp. 99–108, 2010.

[26] C. Carvalho and P. I. Moreira, “Oxidative stress: A major player in cerebrovascular alterations associated to neurodegenerative events,” Frontiers in Physiology, vol. 9, p. 806, 2018.

[27] M. Togha, S. R. Jahromi, Z. Ghorbani, A. Ghaemi, and P. Rafiee, “An investigation of oxidant/ antioxidant balance in patients with migraine: A case-control study,” BMC Neurology, vol. 19, no. 1, p. 323, 2019.

[28] R. J. Wright and T. Stuczynski, “Atomic absorption and flame emission spectrometry,” in Methods of Soil Analysis: Part 3 Chemical Methods. New Jersey: John Wiley & Sons, Inc., 1996. [29] M. S. Blois, “Antioxidant determinations by the use of a stable free radical,” Nature, vol. 181, no. 4617, pp. 1199–1200, 1958.

[30] S. Sitaraman, K. T. Babu, A. Badarinath, A. Pazhanimuthu, and R. Saraswathy, “Assessment of DNA damage using cytokinesis-block micronucleus cytome assay in lymphocytes of dilated cardiomyopathy patients,” Genetics Research, vol. 96, p. e001, 2014.

[31] C. Calabrese, A. Gomez-Duran, A. Reyes, and M. Attimonelli, “Methods for the identification of mitochondrial DNA variants,” in The Human Mitochondrial Genome. Amsterdam, Netherlands: Elsevier, 2020, pp. 243–275.

[32] C. R. Houts, J. S. McGinley, R. J. Wirth, R. Cady, and R. B. Lipton, “Reliability and validity of the 6-item headache impact test in chronic migraine from the PROMISE-2 study,” Quality of Life Research, vol. 30, no. 3, pp. 931–943, 2021.

[33] L. Kelman, “The triggers or precipitants of the acute migraine attack,” Cephalalgia, vol. 27, no. 5, pp. 394–402, 2007.

[34] J. L. Brandes, “The Influence of estrogen on migraine,” JAMA, vol. 295, no. 15, p. 1824, 2006.
[35] J. P. Herman, J. M. McKlveen, S. Ghosal, B. Kopp, A. Wulsin, R. Makinson, J. Scheimann, and B. Myers, “Regulation of the hypothalamicpituitary- adrenocortical stress response,” in Comprehensive Physiology. New Jersey: John Wiley & Sons, Inc., 2016, pp. 603–621.

[36] K. S. Dhillon, J. Singh, and J. S. Lyall, “A new horizon into the pathobiology, etiology and treatment of migraine,” Medical Hypotheses, vol. 77, no. 1, pp. 147–151, 2011.

[37] F. M. Amin, S. Aristeidou, C. Baraldi, E. K. Czapinska-Ciepiela, D. D. Ariadni, D. D. Lenola, C. Fenech, K. Kampouris, G. Karagiorgis, M. Braschinsky, and M. Linde, “The association between migraine and physical exercise,” The Journal of Headache and Pain, vol. 19, no. 1, p. 83, 2018.
[38] Q. Xiong, X. Wang, L. Wang, Y. Huang, X. Tian, Y. Fan, and C.-Y. Lin, “BMP-2 inhibits lung metastasis of osteosarcoma: An early investigation using an orthotopic model,” OncoTargets and Therapy, vol. 11, pp. 7543–7553, 2018.

[39] M. M. Thakkar, “Histamine in the regulation of wakefulness,” Sleep Medicine Reviews, vol. 15, no. 1, pp. 65–74, 2011.

[40] J. Worm, K. Falkenberg, and J. Olesen, “Histamine and migraine revisited: Mechanisms and possible drug targets,” The Journal of Headache and Pain, vol. 20, no. 1, p. 30, 2019.

[41] E. García-Martín, C. Martínez, M. Serrador, H. Alonso-Navarro, P. Ayuso, F. Navacerrada, J. A. G. Agúndez, and F. J. Jiménez-Jiménez, “Diamine oxidase rs10156191 and rs2052129 variants are associated with the risk for migraine,” The Journal of Head and Face Pain, vol. 55, no. 2, pp. 276–286, 2015.

[42] M. Hasanah, H. Hilma, and P. Suwasono, “Antioxidant activity of extract and fractions from Coffee arabica L. leaves by DPPH radical scavenging method,” Scientific Journal of PPIUKM, vol. 3, no. 4, pp. 162–165, 2016.

[43] I. de Boer, G. M. Terwindt, and A. M. J. M. van den Maagdenberg, “Genetics of migraine aura: An update,” The Journal of Headache and Pain, vol. 21, no. 1, p. 64, 2020.

[44] A. Daschner, J. González-Fernández, A. Valls, C. de Frutos, M. Rodero, and C. Cuéllar, “Diamine oxidase levels in different chronic urticaria phenotypes,” Allergologia et Immunopathologia, vol. 43, no. 6, pp. 593–600, 2015.

[45] R. B. Lipton, W. F. Stewart, and A. I. Scher, “Epidemiology and economic impact of migraine,” Current Medical Research and Opinion, vol. 17, pp. s4–s12, 2001, doi: 10.1185/0300799039117005.

[46] O. Hoffman and J. R. Weber, “Review: Pathophysiology and treatment of bacterial meningitis,” Therapeutic Advances in Neurological Disorders, vol. 2, no. 6, pp. 401–412, 2009.

[47] M. Steiner, “Hormones and mood: From menarche to menopause and beyond,” Journal of Affective Disorders, vol. 74, no. 1, pp. 67–83, 2003.

Full Text: PDF

DOI: 10.14416/j.asep.2021.10.012

Refbacks

There are currently no refbacks.

Username
Password
Remember me